DAWN

Day One Biopharmaceutical

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

Ireland

Next Earnings Date

05/05/26

Business Summary

Cimpress operates a mass customization and business services platform, aggregating demand for customized products and services at scale. It generates cash by leveraging centralized production capabilities and technology-driven ordering systems that allow small businesses to procure customized materials efficiently. The economic engine relies on scale efficiencies—high throughput lowers unit costs while recurring small-business demand drives volume consistency. Its moat is operational density and customer integration: once embedded in a client’s procurement workflow, switching costs rise, and scale advantages compound margins when execution is disciplined.

 


VALUATION

P/E

-

Market Cap ($M USD)

$2,217

Forward P/E

-

PEG

-

PRICE TO SALES

14

PRICE TO BOOK

5

EV / EBITDA

-14.4

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.04

Next Year EPS Growth Estimate

-$0.04

Next Year Revenue Growth Estimate

28.30%

Return on Equity (ROE)

-24.30%

FREE CASH FLOW

Operating Margin

-80.80%

Debt-to-Equity

0

Piotroski F-Score

3

Altman Z-Score

18.6

Return on Invested Capital (ROIC)

-22.60%

Current Ratio

8

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Gainseekers Quantitative Analysis

Summary

At 78.1x trailing earnings, CMPR screens optically expensive, but the 17.2 forward P/E tells you the market expects a dramatic earnings normalization. The compression from 78.1 to 17.2 alongside a 1.4 forward PEG implies growth is anticipated but not explosively priced in. However, the balance sheet is not fortress-like: a 2.6 Altman Z-Score places the company in a gray zone rather than distress, yet it does not offer strong downside protection. With a 0.5 Price/Sales multiple and a 10.90% ROIC, the market appears skeptical of sustainability, not blind to value—this is a transitional story priced for recovery, not a clear mispricing screaming deep value.

AI Exposure / Tech Reliance

As a Specialty Business Services company within Industrials, CMPR operates in a space that is increasingly digitized and automation-driven. AI and workflow automation can compress costs and improve personalization at scale, which is critical in business services. The key question is whether operating leverage from tech adoption can reverse the current -4.40% operating margin and turn efficiency gains into durable profitability.

The Bull Case

A GARP or disciplined value investor buys this because the forward setup is materially different from the trailing optics. A 17.2 forward P/E with a 1.4 PEG is reasonable if earnings inflect as projected, and a 10.90% ROIC suggests the core business can generate returns above its cost base when normalized. The Piotroski F-Score of 6 indicates middling but stable fundamentals—not deteriorating chaos. Add 97.50% institutional ownership and a modest 0.5 Price/Sales ratio, and you have a stock that sophisticated capital is willing to hold while waiting for margin repair and earnings realization. If operating margin merely reverts from -4.40% toward positive territory, the valuation multiple likely rerates.

The Bear Case

The red flags are not subtle. Operating margin is -4.40%, Return on Equity is only 5.50%, and Debt/Equity sits at 7.00%—that is aggressive leverage layered onto a business currently losing money operationally. A 0.7 current ratio signals tight liquidity, and the Altman Z-Score of 2.6 does not provide strong bankruptcy-distance comfort. The trailing P/E of 78.1 paired with EPS next year estimated at $0.98 versus current EPS of 9.4 creates a jarring earnings disconnect that demands scrutiny. This is a levered balance sheet dependent on execution; if growth underwhelms, equity holders absorb the volatility first.

Market Sentiment & Smart Money

Short Interest %

11.60%

Analyst Consensus

2.64

Average Analyst Price Target

$20.63

Institutional Ownership %

85.30%

1-Year Beta

0.47

Insider Buying % (6 Mo)

16.90%%

Distance to 52-Week High

100.00%

Distance to 52-Week Low

381.00%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.